ArticleThe Canadian journal of urology2026
Clinical spectrum of retroperitoneal Castleman disease: retrospective analysis of 59 cases in a single Chinese medical center.
Article in The Canadian journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundsCastleman disease (CD) is a rare lymphoproliferative disorder. While its general clinical and pathological features are well-described, detailed data on retroperitoneal CD-a diagnostically challenging location-remain scarce. This study characterizes the clinicopathological profile, management, and long-term outcomes of retroperitoneal CD. The aim of this study is to clarify the clinical and therapeutic characteristics of retroperitoneal CD, and to provide practical evidence for its accurate diagnosis and individualized management in clinical practice.
methodsA retrospective analysis of 59 patients with pathologically confirmed retroperitoneal CD (September 2010-December 2025) was conducted at a single center. Patients were classified as unicentric CD (UCD) or multicentric CD (MCD), with demographic, clinical, imaging, treatment, and follow-up data analyzed.
resultsThe cohort included 52 UCD and 7 MCD patients. UCD patients were younger (median 38 vs. 56 years, p = 0.021), predominantly female (65.40%), and asymptomatic (65.40%). All MCD patients presented with systemic inflammatory symptoms. Perirenal location was the most common (36.54% of UCD). CT consistently showed well-circumscribed, hypervascular masses with intense arterial enhancement. Complete surgical resection of UCD achieved 100% disease-free survival (median follow-up 98.5 months). Multidisciplinary management (surgery, corticosteroids, or rituximab-based therapy) achieved disease control in all MCD patients.
conclusionsRetroperitoneal UCD and MCD are distinct entities. UCD, a typically hyaline vascular type, is often incidentally detected and curable by complete surgical excision. MCD, usually plasma cell type with systemic symptoms, requires systemic therapy. Accurate preoperative diagnosis is critical to guide curative surgery for UCD and multidisciplinary management for MCD.
Indexed as
Identifiers
42682064What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.